A61K 40/421
Immunoglobulin superfamily
Official title: {Immunoglobulin superfamily}
A61K40/421 (Immunoglobulin superfamily) appears on 1,204 US grants and 3,462 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,204
- Published applications
- 3,462
- Assignees
- 958
- Inventors
- 5,318
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 3 |
| 2003 | 0 | 4 |
| 2004 | 0 | 12 |
| 2005 | 3 | 10 |
| 2006 | 1 | 5 |
| 2007 | 1 | 5 |
| 2008 | 5 | 8 |
| 2009 | 0 | 6 |
| 2010 | 6 | 4 |
| 2011 | 3 | 12 |
| 2012 | 1 | 8 |
| 2013 | 3 | 12 |
| 2014 | 7 | 18 |
| 2015 | 9 | 27 |
| 2016 | 11 | 52 |
| 2017 | 22 | 83 |
| 2018 | 38 | 162 |
| 2019 | 56 | 206 |
| 2020 | 95 | 304 |
| 2021 | 118 | 379 |
| 2022 | 135 | 420 |
| 2023 | 147 | 424 |
| 2024 | 167 | 514 |
| 2025 | 211 | 446 |
| 2026 | 157 | 338 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof6 Oct 2026US 12,753,221 B2Abelzeta Inc.
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Compositions and methods for selective protein degradation29 Sep 2026US 12,747,272 B2Novartis AG
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases8 Oct 2026US 2026/0306629 A1
- Methods of sensitizing tumors to treatment with immune checkpoint inhibitors8 Oct 2026US 2026/0306658 A1University of Florida Research Foundation, Inc.
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells384US 6,905,681 B1Genetics Institute, Inc. · 2005
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013